Clinical Trial Update: Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 90Y-SMT487 for symptomatic malignant carcinoid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Carcinoid Tumor

Drugs mentioned

• 90Y-SMT487 (SMT487)

Snippet

Sponsor: Molecular Insight Pharmaceuticals, Inc. | Conditions: Malignant Carcinoid Tumor | Phase 2 | Status: WITHDRAWN